للتسجيل اضغط هـنـا
 |
 |
أنظمة الموقع |
|
تداول في الإعلام |
|
للإعلان لديـنا |
|
راسلنا |
|
التسجيل |
|
طلب كود تنشيط العضوية |
|
تنشيط العضوية |
|
استعادة كلمة المرور |
 |
|
|||||||||||||||||||||||||
|
| ||
14-01-2007, 09:03 PM
|
#31 |
|
مشرف الاسهم الامريكية
تاريخ التسجيل: Jan 2004
المشاركات: 1,262
|
اوراكل عطلتنا عن كثير من الفرص الموجوده في السوق ولن نتوقف عليها .
عموما اللي اخذها كاش مافيه اي مشكلة . وبالنسبة لاهل الاوبشن هناك مزيد من الوقت بما يعادل 65 يوم ستتعدل الامور بمشيئة الله تعالى ولكن من المهم تعديل سعر الدخول اي التعزيز بالنسبة لاهل الاوبشن وسنستمر في متابعتها بمشيئة الله تعالى عموما سنواصل الكتابه عن افضل الشركات التي تستحق ان كون استرونق باي . |
|
|
|
14-01-2007, 09:07 PM
|
#32 | |
|
مشرف الاسهم الامريكية
تاريخ التسجيل: Jan 2004
المشاركات: 1,262
|
اقتباس:
هذه توصيه من العضو Investor1 في منتديات اموال نت رابط الموضوع http://www.amwalnet.com/vb/showthread.php?t=1217 تمنياتي للجميع برحله موفقه بمشيئة الله تعالى |
|
|
|
|
|
20-01-2007, 08:37 PM
|
#33 |
|
متداول جديد
تاريخ التسجيل: Jun 2006
المشاركات: 67
|
مشكور اخي الحبيب
|
|
|
|
|
25-01-2007, 12:38 PM
|
#34 |
|
مشرف الاسهم الامريكية
تاريخ التسجيل: Jan 2004
المشاركات: 1,262
|
--------------------------------------------------------------------------------
WYE ستعلن عن ارباحها في يوم 30 يناير الثلاثاء القادم قبل افتتاح السوق المتوقع من رويتر وزاكس 0.71 سنت ومن نفس الربع للعام الماضي كان 0.59 سنت الشركة تعمل في صناعة الادوية مكرر ربحيتها 17 مره وبالنسبة لصناعتها وقطاعة وللشركات الواقعة في الاس آند بي فهو 20 مره سعرها المستقبلي 58.88$ $ وسعرها السوقي الحالي 51.40$ هناك مشاكل فنيه تمنعني من ارفاق الشارت ولكن تحليلها الفني" الشركة مرتدة من دعم متوسط 30 يوم و أعلى من متوسط 50 و 200 يوم وهي الان داخل تماسك مابين سعر 53.50 قمة وقاع 47.50 وفي حالة كسر التماسك فان السهم اما حركة 5 $ وسيكون الهدف بمشيئة الله تعالى 58.50$ من بدأ الكسر وهو نفس هدف التحليل الاساسي . ليس هناك أي تضخم في مؤشرات الشركة الفنية سواى مؤشر الماكد او RSI للمخاطرين "ركاب الدرجة الاولى " استرايك 52.50 شهر فبراير بسعر 50-55 سنت وامامنا 23 يوم قبل انتهاء الاكسبير لتحقيق الهدف بمشيئة الله تعالى ركاب درجة الضيافة . شهر مارش استرايك 52.5 بسعر 90-95 سنت الوقت المتبقي لانتهاء اكسبير مارش 51 يوم نسبة الاستثمار لاتتجاوز 10% من رأس المال لمضاربي الاوبشن مستثمري الكاش الخروج 58.50$ بمشيئة الله تعالى على ان لايتجاوز الاستثمار اكثر من 25% من رأس المال آخر اخبار الشركة جميعها تصب في صالح الشركة وتتنبأ بمشيئة الله انها سترفع الاوت لوك كونها حصلت على موافقة المكتب الامريكي للاغذية FDA على انتاج دواء بالاضافة الى تسجيلها برائة اختراع جديده وكل هذا حدث في عام 2007 للاستزاده عن اخباره الشركة :WYETH RECEIVES APPROVABLE LETTER FROM FDA FOR PRISTIQ (DESVENLAFAXINE SUCCINATE) 2007 Jan 24 1:41 AM Wyeth Pharmaceuticals, a division of Wyeth, announced that the Company has received an approvable letter from the U.S. Food and Drug Administration (FDA) for Pristiq (desvenlafaxine succinate), a serotonin-norepinephrine reuptake inhibitor (SNRI) studied as a treatment for adult patients with major depressive disorder (MDD). WYETH AND SOLVAY ENTER INTO AN ADDITIONAL NEUROSCIENCE COLLABORATION 2007 Jan 11 5:07 PM Wyeth Pharmaceuticals, a division of Wyeth and Solvay Pharmaceutical B.V. announced that they have entered into a new neuroscience discovery, co-development, and co-commercialization agreement. Under the new agreement, the parties will collaborate in a joint discovery effort targeting the identification of small molecules as potential anti-psychotic medications. Any compounds discovered as part of the research collaboration will be jointly co-owned and patented by Wyeth and Solvay as well as co-developed and co-commercialized by the two companies. WYETH AND CATALYST BIOSCIENCES SIGNES TWO RESEARCH COLLABORATION AND LICENSE AGREEMENTS 2007 Jan 08 5:58 PM Wyeth announced that Catalyst Biosciences, Inc., has signed two research collaboration and license agreements with Wyeth Pharmaceuticals, a division of the Company, having potential total payments of up to $100 million, exclusive of potential royalty payments. The agreements support discovery research and preclinical development using Catalyst's Alterase therapeutics platform (engineered human proteases) directed at two targets, one each in metabolic disease and oncology. The Company will be responsible for the clinical development, manufacturing, and marketing of products developed as a result of these collaborations. The collaboration agreements include upfront license payments, milestone payments, R&D funding and royalties on product sales. FDA GRANTS TORISEL NDA PRIORITY REVIEW STATUS FOR WYETH 2006 Dec 19 6:40 PM Wyeth announced that the U.S. Food and Drug Administration (FDA) has accepted the file and granted priority review status to Wyeth Pharmaceuticals, a division of Company's New Drug Application (NDA) for the investigational drug Torisel (temsirolimus). Wyeth Pharmaceuticals is seeking an indication for Torisel for the treatment of advanced renal cell carcinoma (RCC). A priority designation can be given to an NDA for a drug that, if approved, would be a significant improvement compared with existing treatments. WYETH DECLARES DECLARES PREFERRED STOCK DIVIDEND 2006 Nov 16 11:28 PM Wyeth announced a dividend of $0.50 per share on the outstanding shares of Preferred Stock was declared payable on January 2, 2007 to stockholders of record at the close of business on December 13, 2006 ان اصبت فهي من الله وان اخطأت فهي من نفسي ومن الشيطان الرجيم |
|
|
|
|
25-01-2007, 02:51 PM
|
#35 | |||
|
مشرف الاسهم الامريكية
تاريخ التسجيل: Jan 2004
المشاركات: 1,262
|
اقتباس:
اقتباس:
اقتباس:
لمتابعة التوصيهhttp://www.amwalnet.com/vb/showthread.php?t=1360 |
|||
|
|
|
|
07-02-2007, 04:59 PM
|
#36 |
|
مشرف الاسهم الامريكية
تاريخ التسجيل: Jan 2004
المشاركات: 1,262
|
CSCO
اعلنت امس بعد اغلاق السوق الارباح للربع الثاني وكان الاوت لوك رائع بالنسبة للشركة الشركة بقيادة عميد الكباتنه الكابتن سهيل ومساعدة ابو الفوز منتديات اموال نت http://www.amwalnet.com/vb/showthread.php?t=518&page=18 السهم كاش السعر في البري ماركت 28.60$ الهدف بمشيئة الله تعالى 31$ من اسبوع الى شهر تداول Cisco's 2Q Profit Surges 40 Percent Wednesday February 7, 12:48 am ET By Jordan Robertson, AP Technology Writer Cisco's 2Q Profit Surges 40 Percent, but Investors Unsettled on Growth Fears SAN FRANCISCO (AP) -- Despite a robust second quarter and a sunny financial forecast, networking equipment maker Cisco Systems Inc. is coming under intense scrutiny over fears about the company's ability to sustain its torrid growth rates. ADVERTISEMENT Cisco's stock price rose more than 4 percent in after-hours trading Tuesday after the company said net income for the second quarter surged nearly 40 percent over last year and management raised the revenue outlook for the next two quarters. The company is profiting mightily from an onslaught of service providers scrambling to upgrade their networks and boost bandwidth to handle video downloads that consume thousands of times the network space as e-mail messages. It is also in a financial sweet spot as its routers and switches -- which direct data traffic over computer networks -- are being snapped up in anticipation for the emergence of Internet Protocol Television, or IPTV -- TV delivered over a broadband connection. Some analysts, however, said they spotted potentially troubling issues in the San Jose-based company's latest financials, which were reported after the market closed Tuesday. Of particular concern is a sudden slowdown in orders from U.S. businesses in the quarter, which could portend similar slowdowns in other fast-growing parts of the world, according to Samuel Wilson, a senior analyst for communications equipment for JMP Securities. The segment -- one of Cisco's core businesses -- grew at about a 20 percent clip during the first quarter but suddenly fell to mid-single-digit growth during the second quarter. "We're clearly seeing a deceleration in U.S. enterprise -- but the magic question is, is it a one-time bump? Or is it something more?" Wilson said. "If it's something more, it will start to affect Cisco's business." But by and large, investors reacted warmly to Cisco's enviable earnings growth and bullish forecast for the rest of the fiscal year. For the quarter ended Jan. 27, Cisco's net income was $1.9 billion, or 31 cents per share, compared with $1.4 billion, or 22 cents per share, for the same period last year. Excluding one-time charges, Cisco said Tuesday it earned $2.1 billion for the quarter, or 33 cents per share. The technology bellwether said revenue for the quarter was $8.4 billion, a 27 percent jump from the $6.6 billion in the same period last year. Analysts were expecting Cisco to earn, on average, 31 cents per share on $8.28 billion in revenue, according to a survey by Thomson Financial. But some analysts have expressed concerns about slowing growth as the initial boost from Cisco's acquisition of Scientific-Atlanta Inc. wears off. Cisco said $639 million of its second-quarter sales came from Scientific-Atlanta, the world's second-largest cable television box seller, which Cisco acquired for $6.9 billion in the third quarter of last year. Cisco's stock had also been downgraded by several analysts before the earnings release on fears the current upgrade cycle -- the largest since the pre-Y2K scramble -- was starting to wind down. However, Cisco Chief Executive John Chambers dismissed concerns about a looming slowdown in the networking industry. He said in an interview with The Associated Press that the company's long-term strategy is centered on the rising demand for sophisticated equipment to manage the convergence of data, voice and video transmissions over the network. "It was clearly another very strong quarter -- that really is the proof point that our vision of how the industry is playing out is working," Chambers said. The company's earnings release sparked an initial sell-off, but shares rebounded after management issued an upbeat financial forecast during the conference call. The company expects third-quarter revenue of $8.7 billion to $8.8 billion, an increase of 19 to 20 percent over last year, Cisco Chief Financial Officer Dennis Powell said. However, those results include an "above-normal" boost from Scientific-Atlanta sales. Cisco's standalone growth rate is still in the 15 percent to 17 percent range and above the company's previous forecasts, Powell said. The momentum is expected to continue into the fourth quarter, with Cisco forecasting revenue of $9 billion to $9.3 billion, an increase of 14 percent to 16 percent over the same period last year. Chambers said the company will continue to benefit from a promising pipeline of new routing and switching products and continued strong sales worldwide. "This obviously indicates a high degree of confidence in our strategy and business momentum," Chambers said on the conference call. "We believe that our vision, strategy, and execution are in great shape." The results were announced after financial markets ended regular trading. Earlier, shares of Cisco lost 23 cents to close at $27.28 on the Nasdaq Stock Market. Shares gained $1.20 in extended-session trading. |
|
|
|
|
08-02-2007, 05:05 PM
|
#37 | ||
|
مشرف الاسهم الامريكية
تاريخ التسجيل: Jan 2004
المشاركات: 1,262
|
اقتباس:
AMX اعلنت الشركة بعد اغلاق السوق نتائجها وهي على النحو التالي اقتباس:
|
||
|
|
|
|
07-09-2007, 06:33 PM
|
#38 |
|
متداول جديد
تاريخ التسجيل: Sep 2004
المشاركات: 50
|
بارك الله فيك وجزاك الله خير
|
|
|
|
|
07-09-2007, 07:42 PM
|
#39 |
|
متداول نشيط
تاريخ التسجيل: Mar 2006
المشاركات: 1,293
|
شركة غنية عن التعريف بارك الله فيك
|
|
|
|
 |
| مواقع النشر (المفضلة) |
|
|
